Trials / Recruiting
RecruitingNCT06419361
[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- First Affiliated Hospital of Chongqing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\[68Ga\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [68Ga]Ga-Sa-DABI-4 | Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4. |
Timeline
- Start date
- 2024-05-30
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2024-05-17
- Last updated
- 2025-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06419361. Inclusion in this directory is not an endorsement.